News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
125,839 Results
Type
Article (6181)
Company Profile (26)
Press Release (119632)
Multimedia
Podcasts (17)
Webinars (2)
Section
Business (35862)
Career Advice (163)
Deals (5972)
Drug Delivery (11)
Drug Development (6610)
Employer Resources (20)
FDA (3569)
Job Trends (2542)
News (53170)
Policy (4582)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
Academia (493)
Accelerated approval (3)
Adcomms (1)
Allergies (13)
Alliances (12221)
ALS (17)
Alzheimer's disease (401)
Antibody-drug conjugate (ADC) (19)
Approvals (3631)
Artificial intelligence (181)
Autoimmune disease (17)
Automation (12)
Bankruptcy (55)
Best Places to Work (2091)
BIOSECURE Act (2)
Biosimilars (11)
Biotechnology (17)
Bladder cancer (34)
Brain cancer (10)
Breast cancer (162)
Cancer (966)
Cardiovascular disease (64)
Career advice (148)
Career pathing (2)
CAR-T (24)
CDC (4)
Celiac Disease (1)
Cell therapy (80)
Cervical cancer (10)
Clinical research (5334)
Collaboration (387)
Compensation (46)
Complete response letters (6)
COVID-19 (543)
CRISPR (15)
C-suite (144)
Cystic fibrosis (14)
Data (768)
Decentralized trials (1)
Denatured (3)
Depression (24)
Diabetes (38)
Diagnostics (6163)
Digital health (20)
Diversity (5)
Diversity, equity & inclusion (5)
Drug discovery (31)
Drug pricing (15)
Drug shortages (2)
Duchenne muscular dystrophy (13)
Earnings (11896)
Editorial (8)
Employer branding (5)
Employer resources (20)
Events (15979)
Executive appointments (183)
FDA (4068)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (2)
Funding (303)
Gene editing (27)
Generative AI (12)
Gene therapy (82)
GLP-1 (83)
Government (829)
Grass and pollen (1)
Guidances (71)
Healthcare (3560)
HIV (9)
IgA nephropathy (3)
Immunology and inflammation (15)
Immuno-oncology (5)
Indications (8)
Infectious disease (595)
Inflammatory bowel disease (17)
Inflation Reduction Act (2)
Influenza (26)
Intellectual property (31)
Interviews (21)
IPO (2150)
IRA (4)
Job creations (492)
Job search strategy (134)
JPM (2)
Kidney cancer (6)
Labor market (3)
Layoffs (36)
Leadership (4)
Legal (675)
Liver cancer (17)
Longevity (2)
Lung cancer (108)
Lymphoma (64)
Machine learning (8)
Management (4)
Manufacturing (123)
MASH (23)
Medical device (2868)
Medtech (2882)
Mergers & acquisitions (4054)
Metabolic disorders (100)
Multiple sclerosis (43)
NASH (3)
Neurodegenerative disease (57)
Neuropsychiatric disorders (5)
Neuroscience (562)
NextGen: Class of 2026 (1036)
Non-profit (804)
Now hiring (5)
Obesity (33)
Opinion (42)
Ovarian cancer (32)
Pain (13)
Pancreatic cancer (34)
Parkinson's disease (36)
Partnered (5)
Patents (57)
Patient recruitment (50)
Peanut (5)
People (10706)
Pharmaceutical (1)
Pharmacy benefit managers (5)
Phase 1 (1720)
Phase 2 (2229)
Phase 3 (2029)
Pipeline (766)
Policy (19)
Postmarket research (235)
Preclinical (749)
Press Release (12)
Prostate cancer (78)
Psychedelics (4)
Radiopharmaceuticals (132)
Rare diseases (102)
Real estate (1005)
Recruiting (10)
Regulatory (3714)
Reports (10)
Research institute (525)
Resumes & cover letters (20)
Rett syndrome (5)
RSV (6)
Schizophrenia (6)
Series A (42)
Series B (36)
Service/supplier (1)
Sickle cell disease (19)
Special edition (2)
Spinal muscular atrophy (13)
Sponsored (9)
Startups (759)
Stomach cancer (3)
Supply chain (11)
Tariffs (1)
The Weekly (14)
Vaccines (87)
Venture capital (15)
Weight loss (17)
Women's health (25)
Worklife (1)
Date
Last 7 days (95)
Last 30 days (350)
Last 365 days (4559)
2026 (454)
2025 (4744)
2024 (5801)
2023 (6924)
2022 (11190)
2021 (10711)
2020 (10266)
2019 (7983)
2018 (6092)
2017 (6137)
2016 (6149)
2015 (6946)
2014 (5188)
2013 (4567)
2012 (4855)
2011 (5104)
2010 (4406)
Location
Africa (154)
Alabama (8)
Alaska (2)
Arizona (77)
Arkansas (2)
Asia (6133)
Australia (1574)
California (1645)
Canada (446)
China (71)
Colorado (129)
Connecticut (82)
Delaware (13)
Europe (17469)
Florida (224)
Georgia (76)
Idaho (7)
Illinois (189)
India (15)
Indiana (65)
Iowa (7)
Japan (53)
Kansas (16)
Kentucky (9)
Louisiana (7)
Maine (23)
Maryland (174)
Massachusetts (876)
Michigan (105)
Minnesota (142)
Mississippi (1)
Missouri (46)
Montana (6)
Nebraska (10)
Nevada (5)
New Hampshire (23)
New Jersey (323)
New Mexico (17)
New York (553)
North Carolina (261)
North Dakota (7)
Northern California (853)
Ohio (58)
Oklahoma (5)
Oregon (10)
Pennsylvania (186)
Rhode Island (7)
South America (204)
South Carolina (9)
Southern California (590)
Tennessee (66)
Texas (414)
United States (6135)
Utah (178)
Virginia (73)
Washington D.C. (11)
Washington State (146)
West Virginia (1)
Wisconsin (67)
Wyoming (2)
125,839 Results for "blue earth diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
First Patients in the UK Receive Doses of Blue Earth Therapeutics’ Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate Resistant Prostate Cancer
January 16, 2026
·
7 min read
Press Releases
Blue Earth Therapeutics Presents Modelling Data Supporting Early Dose Intensification of Lutetium (177Lu) rhPSMA-10.1 Injection in mCRPC
October 7, 2025
·
5 min read
Pharm Country
Blue Earth Diagnostics Highlights Presentations on POSLUMA®
Blue Earth Diagnostics Highlights Presentations on POSLUMA® at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to be held June 8 to 11, 2024, in Toronto, Canada.
May 29, 2024
·
10 min read
Mergers & acquisitions
Amgen Makes up to $840M Cancer Play With Dark Blue Takeover
The acquisition is centered on Dark Blue Therapeutics’ small-molecule degrader of the MLLT1 and MLLT3 proteins, which is being tested for acute myeloid leukemia.
January 7, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Blue Earth Diagnostics Reinforces Leadership in Prostate Cancer Imaging and Highlights Expanding Pipeline at Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025
June 18, 2025
·
11 min read
Press Releases
Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial
June 25, 2025
·
5 min read
Pharm Country
Blue Earth Diagnostics Highlights Results of Studies Evaluating Impact of Urinary Activity on Image Interpretation and Performance of POSLUMA® (Flotufolastat F 18) and 18F-Flotufolastat PET in Prostate Cancer
Blue Earth Diagnostics announced highlights from clinical studies conducted by its collaborators at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, 2024.
June 10, 2024
·
9 min read
Business
SHINE Technologies Partners with Blue Earth Therapeutics for First Supply of Ilumira from Its New Facility
SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, today announced a new partnership with Blue Earth Therapeutics, a Bracco company and recognized leader in the development of innovative radiopharmaceuticals.
June 6, 2024
·
3 min read
Pharm Country
Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting
Blue Earth Diagnostics Highlights Presentations on POSLUMA ® (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting.
September 27, 2023
·
7 min read
Drug Development
Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU
Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA ® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU.
January 25, 2024
·
11 min read
1 of 12,584
Next
